GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Clinical trials for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR explained in plain language.
Never miss a new study
Get alerted when new GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR trials appear
Sign up with your email to follow new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Alpha-Particle therapy shows promise for Hard-to-Treat tumors
Disease control Recruiting nowThis study tests a new type of radiation therapy that delivers alpha particles directly to tumor cells. It is for people with advanced neuroendocrine tumors or meningioma that cannot be removed by surgery or have spread. The goal is to find the safest dose and see if it shrinks t…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Perspective Therapeutics • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC
-
New study tracks targeted radiation for gut and pancreas tumors
Disease control Recruiting nowThis study is looking at how well a treatment called PRRT works for people with neuroendocrine tumors that started in the stomach, intestines, or pancreas. PRRT uses a radioactive drug to target and kill cancer cells. Researchers will track patient details, tumor changes, surviva…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Sponsor: Methodist Health System • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New radioactive drug targets Hard-to-Treat tumors
Disease control Recruiting nowThis early-phase study tests a new radioactive drug called RYZ401 in people with neuroendocrine tumors and other solid tumors that have a specific marker (somatostatin receptors). The main goals are to find the safest dose and schedule, and to see if the drug can shrink tumors. A…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE1 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC
-
Radioactive drug plus surgery: new hope for neuroendocrine cancer?
Disease control Recruiting nowThis early-phase study tests whether giving a radioactive drug (Lutathera) before and after surgery is safe and feasible for people with advanced neuroendocrine tumors that have spread to the liver or lymph nodes. About 10 participants will receive two cycles of the drug, then un…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC
-
Hope for rare cancers: new immunotherapy combo tested in nationwide trial
Disease control Recruiting nowThis study tests a combination of two immunotherapy drugs (domvanalimab and zimberelimab) in people with five types of rare advanced cancers that have not responded to standard treatment. The goal is to see if this treatment can shrink tumors or stop them from growing for at leas…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 09, 2026 12:08 UTC
-
New hope for gut cancer patients who failed standard therapy
Disease control Recruiting nowThis study tests a new drug called RYZ101 in people with advanced neuroendocrine tumors of the gut or pancreas that cannot be removed by surgery and have grown after prior treatment with a type of radiation therapy (177Lu-SSA). The study has two parts: first, finding the right do…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE3 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated Jun 08, 2026 13:08 UTC
-
New study aims to predict which patients benefit from targeted radiation for rare gut tumors
Knowledge-focused Recruiting nowThis study enrolls 80 people with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who are scheduled for peptide receptor radionuclide therapy (PRRT). Researchers will collect PET-MRI scans, genetic profiles, and other data before, during, and after treatment. The…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 16, 2026 21:48 UTC
-
Could diet be key to better outcomes for Slow-Growing tumors?
Knowledge-focused Recruiting nowThis study looks at whether nutritional status is linked to prognosis in adults with gastroenteropancreatic neuroendocrine tumors (NETs), which are slow-growing cancers of the digestive system. Researchers will assess malnutrition in 100 participants aged 18 to 70 who have been t…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jun 10, 2026 13:24 UTC